Moberg Pharma AB: Moberg Pharma and Karo Healthcare expand collaboration for MOB-015/Terclara to Australia, New Zealand, South Korea and Taiwan

AI Briefing

• – Moberg Pharma AB and Karo Healthcare expand collaboration for MOB-015/Terclara to Australia, New Zealand, South Korea and Taiwan
• – Exclusivity agreement covers commercialization of MOB-015 for nail fungus treatment
• – MOB-015/Terclara aims to treat nail fungus with improved efficacy and safety profile